Previous 10 | Next 10 |
Gainers: Datasea (DTSS) +90%.Lexicon Pharmaceuticals (LXRX) +85%.Pennsylvania Real Estate Investment Trust (PEI) +50%.DPW Holdings (DPW) +36%.Organogenesis (ORGO) +34%.Acacia Communications (ACIA) +33%.Bicycle Therapeutics (BCYC) +31%.AeroVironment (AVAV) +29%.Maxar Technologie...
Gainers: Organogenesis Holdings (ORGO) +33%. Lexicon Pharmaceuticals (LXRX) +30%. NantKwest (NK) +27%. Oragenics (OGEN) +25%. Bicycle Therapeutics (BCYC) +23%.Losers: Viveve Medical (VIVE) -23%. Cassava Sciences (SAVA) -12%. Timber Pharmaceuticals (TMBR) -11%. InflaRx N.V. (IFRX) -9...
Are These The Best Biotech Stocks To Buy Now? Biotech stocks were one of the biggest winners in the stock market last year. While many stocks on the market have yet to recover fully from the crash in March, top biotech stocks have thrived. The SPDR S&P Biotech Index ...
Alzheimer's Disease is one of the greatest challenges facing the world today, and a larger storm is coming. Cassava Sciences' Alzheimer's drug Simufilam has a unique method of action, and is consistently shown to be safe and effective. Simufilam has an excellent chance to be appro...
AUSTIN, Texas, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced the appointment of James Kupiec, MD, to the newly created position of Chief Clinical Development Officer. Dr. ...
Tesla is now a S&P 500 member, a watershed moment for one of the biggest stock market stories in our lifetimes. The question is - is inclusion vindication, or the last bullet left in a (very very successful) bull case? We talk with one of the longest-term and most notorious sh...
Cassava Sciences has had a bit of a rollercoaster this year. Their phase 2 tests failed. Then they looked again and maybe something interesting. They've also raised $75 million which will keep them going but no more than that. It'll not pay for phase 3 testing, no way. Effectively...
FN Media Group Presents GlobalInvestmentDaily.com Market Commentary London – December 1, 2020 – Thanks in large part to the global COVID-19 pandemic, 2020 has been a year of tremendous challenges and adversity. But those historic challenges have also ...
Cassava Sciences (SAVA) says that the World Health Organization ((WHO)) advised the United States Adopted Names Council ((USAN)) to modify the chemical name of the Company’s lead drug candidate to 'simufilam' from sumifilam in patients with Alzheimer’s disease.USAN has...
AUSTIN, Texas, Nov. 27, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) today announced that the World Health Organization (WHO) advised the United States Adopted Names Council (USAN) to modify the chemical name of the Company’s lead drug candidate to ‘simuf...
News, Short Squeeze, Breakout and More Instantly...
Cassava Sciences Inc. Company Name:
SAVA Stock Symbol:
NYSE Market:
2024-05-08 16:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
AUSTIN, Texas, May 08, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company”), a biotechnology company focused on Alzheimer’s disease, today announced total gross proceeds of over $125 million from cash-exercises of warrants that were previously distri...
2024-05-07 10:47:03 ET ProShares UltraPro Short QQQ (SQQQ) SQQQ is trading DOWN for the last 4 days, and it at trading at $10.69 with volume of 30,905,666 and a one day change of $-0.01 (-0.09%). ProShares UltraPro Short QQQ has a 52-week low of 10.05 and a 52-week high of $29.28. T...